이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

The Application of Lifestyle Enhancing Validated Integrative Therapies for Everyday Pain in Cirrhosis (ALLEVIATE-C)

2026년 8월 25일 업데이트: University of Pennsylvania

The goal of this clinical trial is to test a low-touch vs high-touch drug-free pain self-management program that may help lower pain and improve quality of life for adults with cirrhosis and pain. Participants are assigned by chance to one of two study groups. The groups receive different levels of support. The main questions it aims to answer are:

Do the programs help lower pain?
Do the programs improve quality of life?
Is one program more effective than the other?

Researchers will compare a low-touch self management program to a high-touch self-management program to see if the programs help manage pain.

Participants in the low-touch arm will:

Learn new ways to manage pain without medication
Receive access to the self-guided digital self-management platform
Receive general behavioral text message nudges
Receive a free Fitbit to keep

Participants in the high-touch arm will:

Learn new ways to manage pain without medication
Receive tailored access to the self-guided digital self-management platform
Received individualized pain coaching and optional group coaching sessions
Participate in a structured walking or meditation curriculum
Receive a free Fitbit to keep

연구 개요

상태

아직 모집하지 않음

정황

간경변, 간

개입 / 치료

상세 설명

The Application of Lifestyle Enhancing Validated Integrative Therapies for Everyday Pain in Cirrhosis (ALLEVIATE-C) is a multicenter, individual-level, parallel-arm, 1:1 randomized superiority trial with a 4-week run-in period followed by 48 weeks of intervention and follow-up. The study will compare effectiveness of a high-touch vs low-touch self-management program to treat chronic pain among patients with cirrhosis.

Participants in the high-touch arm receive tailored digital self-management program, individualized pain coaching, and a structured walking or meditation curriculum selected through Active Choice as the primary behavioral focus for 48 weeks. The high-touch arm also includes on-demand coaching for low-pain self-efficacy and optional group coaching sessions.

Participants in the low-touch arm receive access to the self-guided digital self-management platform with automated educational content and behavioral nudges for 48 weeks.

Remote or in-person follow up study visits will occur at 12, 24, 36, and 48 weeks.

Endpoints include:

Primary: Change from baseline in pain interference over 48 weeks (measured using the Pain, Enjoyment of Life, and General Activity (PEG) scale).
Secondary: Health-related quality of life, cognitive function, average daily step count, pain-related disability, nociplastic pain, cumulative exposure to potentially risky medications, days alive and out of the hospital, pain management strategies, intervention engagement, and care partner burden.
Implementation: Acceptability, feasibility, intervention fidelity, and barriers and facilitators to implementation.

연구 유형

중재적

등록 (추정된)

625

단계

해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

미국
- California
  - San Francisco, California, 미국, 94143
    - University of California San Francisco
    - 연락하다:
      
      Rayshawnda Davis, MS
      
      이메일: rayshawnda.davis@ucsf.edu
    - 수석 연구원:
      
      Jessica Rubin, MD, MPH
- Florida
  - Miami, Florida, 미국, 33136
    - University of Miami
    - 수석 연구원:
      
      David Goldberg, MD
    - 연락하다:
      
      Cindy Delgado
      
      전화번호: 305-243-5799
      
      이메일: cdelgado5@med.miami.edu
- Maryland
  - Baltimore, Maryland, 미국, 21205
    - John Hopkins University
    - 연락하다:
      
      Lisa Datta
      
      전화번호: (443) 831-1940
      
      이메일: ldatta1@jh.edu
    - 수석 연구원:
      
      Alexandra Strauss, MD, PhD
- Michigan
  - Ann Arbor, Michigan, 미국, 48109
    - University of Michigan
    - 수석 연구원:
      
      Elliot Tapper, MD
    - 연락하다:
      
      Samantha Nikirk, MPH
      
      전화번호: 7342324182
      
      이메일: samjwalk@med.umich.edu
- Minnesota
  - Rochester, Minnesota, 미국, 55905
    - Mayo Clinic
    - 수석 연구원:
      
      Douglas Simonetto, MD
    - 연락하다:
      
      Amy Olofson, RN
      
      전화번호: (507) 538-6547
      
      이메일: olofson.amy@mayo.edu
- New York
  - New York, New York, 미국, 10032
    - Columbia University
    - 수석 연구원:
      
      Elizabeth Verna, MD
    - 연락하다:
      
      Geena Heitmann, MPH
      
      전화번호: (212) 305-3839
      
      이메일: gg2827@cumc.columbia.edu
- Pennsylvania
  - Philadelphia, Pennsylvania, 미국, 19104
    - University of Pennsylvania
    - 연락하다:
      
      Richard Mason, PharmD
      
      전화번호: 215-349-8986
      
      이메일: Richard.Mason@pennmedicine.upenn.edu
    - 연락하다:
      
      Jacqueline Theroux, MPH
      
      전화번호: 2156623904
      
      이메일: Jacqueline.Theroux@pennmedicine.upenn.edu
    - 수석 연구원:
      
      Marina Serper, MD, MS
- Tennessee
  - Nashville, Tennessee, 미국, 37232
    - Vanderbilt University
    - 연락하다:
      
      Ashley Spann, MD, MS
      
      전화번호: (615) 421-6137
      
      이메일: ashley.spann@vumc.org
    - 수석 연구원:
      
      Ashley Spann, MD, MS

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

성인
고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Patient Inclusion Criteria:

Age > 18 years of age.
Clinical diagnosis of cirrhosis established by any one of the following:
1. Liver biopsy consistent with cirrhosis.
2. Noninvasive evidence of cirrhosis, defined as ≥2 of the following criteria:
  - Imaging (Ultrasound (US), Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)) demonstrating cirrhosis liver morphology (e.g., 'cirrhosis', cirrhotic appearing', 'nodular') with supportive findings (e.g., splenomegaly or recanalized umbilical vein).
  - Transient elastography (TE) (FibroScan) liver stiffness > 12.5 kilopascal (kPa) with IQR/Median <30% or Magnetic resonance elastography > 5.0 kPa
  - Laboratory evidence including AST/platelet ratio index (APRI) >2.0, FIB-4 >2.67 or Platelet count <150 x 10⁹/L.
  - CT, MRI, or Esophagogastroduodenoscopy (EGD) showing the presence of esophageal varices
3. History of at least one cirrhosis complication, including variceal hemorrhage, hepatocellular carcinoma (HCC), ascites, or hepatic encephalopathy.
Liver transplant recipients are eligible if the transplanted cirrhotic allograft meets the above criteria.
Chronic pain, defined as a Pain, Enjoyment of Life, and General Activity (PEG) scale score > 4, assessed during screening prior to consent.
Ability to ambulate (walk), either independently or with the use of assistive devices.
Reliable access to Wi-Fi or cellular data.
Ownership of, or reliable access to, a smartphone with the ability and willingness to receive study-related text messages.
Ability to speak and read English or Spanish.

Patient Exclusion Criteria:

Acute pain due to injury (e.g., surgery, fracture, trauma, burn) within 28 days.
Diagnosed or suspected noncirrhotic portal hypertension.
Episode of overt hepatic encephalopathy (HE) within 28 days prior to consent.
a. Overt HE is defined as acute disorientation requiring hospitalization or initiation of HE-directed therapy (e.g., lactulose, fluids, rifaximin) with diagnosis made by a gastroenterologist, hepatologist, or study investigator and resolution following therapy.
Model for End-Stage Liver Disease - Na (MELD-Na) score > 25 calculated using the UNOS algorithm.
a. Participants with MELD-Na > 25 due to clinically stable end-stage renal disease (ESRD) may be eligible if total bilirubin < 5 mg/dL.
Advanced hepatocellular carcinoma (HCC) defined as Barcelona Clinic Liver Cancer (BCLC) stage > C, or current treatment with systemic therapy for HCC (e.g., sorafenib, atezolizumab/bevacizumab, durvalumab/tremelimumab, regorafenib, cabozantinib).
> 2 paracenteses within 56 days prior to consent.
Fontan-associated liver disease without cirrhosis on biopsy.
Inpatient hospital admission lasting > 24 hours within 28 days prior to consent.
Active metastatic solid malignancy or acute leukemia within 3 years prior to consent.
Estimated life expectancy < 1 year, as determined by the study investigator.
Planned living donor liver transplantation within 12 weeks of enrollment.
Routine meditation practice, defined as meditation occurring weekly or more frequently.
Inability to participate in study procedures, including inability to read study materials, cognitive impairment, or psychiatric illness that would preclude participation in the opinion of the investigator.
Concurrent enrollment in another nonpharmacologic pain management study or formal pain management program utilizing nonpharmacologic approaches.
Deemed unsuitable for participation by the study investigator.
Prisoners.

Care Partner Inclusion Criteria

Age > 18 years of age.
Informal caregiver of a participant enrolled in ALLEVIATE-C
Ability to speak and read English or Spanish.

Care Partner Exclusion Criteria

Inability to participate in study procedures, including inability to read study materials, cognitive impairment, or psychiatric illness that would preclude participation in the opinion of the investigator.
Deemed unsuitable for participation by the study investigator.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

주 목적: 지지 요법
할당: 무작위
중재 모델: 병렬 할당
마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔 참가자 그룹 / 팔 시험 프로토콜에 따라 특정 중재/치료를 받거나 중재를 받지 않는 임상 시험 참가자 그룹 또는 하위 그룹입니다.	개입 / 치료 개입 / 치료 임상 연구의 초점이 되는 프로세스 또는 작업입니다. 개입에는 약물, 의료 기기, 절차, 백신 및 조사 중이거나 이미 사용 가능한 기타 제품이 포함됩니다. 개입에는 교육이나 식이요법 및 운동 수정과 같은 비침습적 접근법도 포함될 수 있습니다.
실험적: High-Touch Participants receive tailored digital self-management program, individualized pain coaching, and a structured walking or meditation curriculum selected through Active Choice as the primary behavioral focus for 48 weeks. The high-touch arm also includes on-demand coaching for low-pain self-efficacy and optional group coaching sessions.	행동: High-touch self-management program Tailored digital self-management program, individualized pain coaching, and a structured walking or meditation curriculum selected through Active Choice as the primary behavioral focus for 48 weeks. On-demand coaching for low-pain self-efficacy and optional group coaching sessions.
실험적: Low-Touch Participants receive access to the self-guided digital self-management platform with automated educational content and behavioral nudges for 48 weeks.	행동: Low-touch self-management program Access to the self-guided digital self-management platform with automated educational content and behavioral nudges for 48 weeks.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정	측정값 설명	기간
Pain Interference 기간: 48 weeks	Change from baseline in pain interference over 48 weeks, measured by repeated assessments using the Pain, Enjoyment of life, and General activity (P.E.G.) scale at 12, 24, 36, and 48 weeks, and compared between the two groups. The PEG is a three-item scale with a minimum value of 0 and a maximum value of 10 for each question. A higher score indicates a worse outcome.	48 weeks

2차 결과 측정

결과 측정	측정값 설명	기간
Health-related quality of life 기간: 48 weeks	Change from baseline in health-related quality of life over 48 weeks, assessed using the PROMIS-29+2 Profile v2.1 (PROPr) domain T-scores (physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities, and pain interference) as well as the multidomain PROPr summary score. Most domains of the PROPr are ranked on a scale with a minimum of 1 and a maximum of 5. Scores for domains are assessed differently. For fatigue, anxiety, depression, sleep disturbance, and pain interference, a higher score indicates a worse outcome. For physical function, cognitive function, and ability to participate in social roles, a higher score indicates a better outcome. Pain intensity is separately ranked on a scale of 0 to 10, with a higher score indicating a worse outcome.	48 weeks
Average daily step count 기간: 48 weeks	Change from baseline in average daily step count over 48 weeks, captured via wearable fitness trackers (Fitbit).	48 weeks
Pain-related disability 기간: 48 weeks	Change from baseline in pain-related disability at 48 weeks, measured by the Pain Disability Index (PDI) total score. The PDI is a 7-item scale with a minimum value of 0 and a maximum value of 10 for each question. A higher score indicates a worse outcome.	48 weeks
Severity of nociplastic pain 기간: 52 weeks	Change from baseline in severity of nociplastic pain over 52 weeks, assessed using the Fibromyalgia Severity Score (FSS).	52 weeks
Cumulative exposure to potentially risky medications 기간: 48 weeks	Change from baseline in cumulative exposure to potentially risky medications over 48 weeks, quantified using the Opioid Total Standardized Dose (TSD) across medication classes relevant to cirrhosis.	48 weeks
Days alive and out of the hospital 기간: 48 weeks	Days alive and out of the hospital (DAOH) over 48 weeks, incorporating hospitalizations, emergency room (ER) visits, and death.	48 weeks
Animal Naming Test 기간: 48 weeks	Change in cognitive function, measured by the Animal Naming Test (ANT), over 48 weeks.	48 weeks
Patient-reported use and perceived effectiveness of pharmacologic and non-pharmacologic pain management strategies 기간: 52 weeks	Change from baseline in patient-reported use and perceived effectiveness of pharmacologic and non-pharmacologic pain management strategies at 52 weeks, assessed using a structured study-specific pain management inventory.	52 weeks
Caregiver burden 기간: 48 weeks	Change from baseline in care partner caregiver burden, measured by the 12-item Zarit Burden Interview (ZBI-12), over 48 weeks.	48 weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

University of Pennsylvania

협력자

Patient-Centered Outcomes Research Institute

Johns Hopkins University

Mayo Clinic

University of Miami

Columbia University

University of Michigan

University of California, San Francisco

Vanderbilt University Medical Center

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

유용한 링크

Website to be used in study intervention

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2027년 1월 1일

기본 완료 (추정된)

2030년 3월 1일

연구 완료 (추정된)

2030년 6월 1일

연구 등록 날짜

최초 제출

2026년 8월 14일

QC 기준을 충족하는 최초 제출

2026년 8월 25일

처음 게시됨 (실제)

2026년 8월 28일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 8월 28일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 8월 25일

마지막으로 확인됨

2026년 8월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

MP-2025C1-43619

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Dissemination of results from this trial will be conducted in accordance with policies and procedures established by the Executive Committee. All abstracts, presentations, and manuscripts arising from this study will be reported to the Patient-Centered Outcomes Research Institute (PCOR)I in compliance with contractual requirements.

Fundamentally, PCORI's Policy for Data Management and Data Sharing articulates PCORI's expectation that Awardees make data and data documentation (Full Data Package) from their PCORI-funded research projects available to third-party requestors.

The deposition is centered around the Full Data Package, which is comprised of the Analyzable Data Set, Full Protocol, metadata, data dictionary, full statistical analysis plan (including all amendments and all documentation for additional work processes), and analytic code from a PCORI-funded research project.

IPD 공유 기간

Results submitted to ClinicalTrials.gov or other applicable database: 9/1/2030 Contract term date: 3/31/2032

IPD 공유 액세스 기준

Results submitted to ClinicalTrials.gov or other applicable database

IPD 공유 지원 정보 유형

연구_프로토콜
수액
ICF
ANALYTIC_CODE
CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

The Application of Lifestyle Enhancing Validated Integrative Therapies for Everyday Pain in Cirrhosis (ALLEVIATE-C)

연구 개요

상태

정황

개입 / 치료

상세 설명

연구 유형

등록 (추정된)

단계

연락처 및 위치

연구 장소

참여기준

자격 기준

공부할 수 있는 나이

건강한 자원 봉사자를 받아들입니다

설명

공부 계획

연구는 어떻게 설계됩니까?

디자인 세부사항

팔의 수

무기와 개입

참가자 그룹 / 팔

개입 / 치료

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정

측정값 설명

기간

2차 결과 측정

결과 측정

측정값 설명

기간

공동 작업자 및 조사자

스폰서

협력자

간행물 및 유용한 링크

유용한 링크

연구 기록 날짜

연구 주요 날짜

연구 시작 (추정된)

기본 완료 (추정된)

연구 완료 (추정된)

연구 등록 날짜

최초 제출

QC 기준을 충족하는 최초 제출

처음 게시됨 (실제)

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

QC 기준을 충족하는 마지막 업데이트 제출

마지막으로 확인됨

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

IPD 계획 설명

IPD 공유 기간

IPD 공유 액세스 기준

IPD 공유 지원 정보 유형

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

미국 FDA 규제 기기 제품 연구